{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:46:47Z","timestamp":1787510807410,"version":"build-2736575974"},"reference-count":75,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070998"],"award-info":[{"award-number":["32070998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271054"],"award-info":[{"award-number":["32271054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101302"],"award-info":[{"award-number":["82101302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","award":["BE2020667"],"award-info":[{"award-number":["BE2020667"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jpain.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T18:53:16Z","timestamp":1676141596000},"page":"1142-1150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["PD-1: A New Candidate Target for Analgesic Peptide Design"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-753X","authenticated-orcid":false,"given":"Long","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-136X","authenticated-orcid":false,"given":"Yu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-0788","authenticated-orcid":false,"given":"Yongjiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5982-4002","authenticated-orcid":false,"given":"Pengjie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2023.02.002_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ddtec.2011.07.007","article-title":"Opioid peptides: potential for drug development","volume":"9","author":"Aldrich","year":"2012","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0002","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/psc.2762","article-title":"N-terminal guanidinylation of the cyclic 1,4-ureido-deltorphin analogues: the synthesis, receptor binding studies, and resistance to proteolytic digestion","volume":"21","author":"Bankowski","year":"2015","journal-title":"J Pept Sci"},{"key":"10.1016\/j.jpain.2023.02.002_bib0003","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fphar.2020.00188","article-title":"Functional selectivity and antinociceptive effects of a novel KOPr agonist","volume":"11","author":"Bedini","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0005","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2023.02.002_bib0006","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neuron.2014.01.018","article-title":"Transmitting pain and itch messages: a contemporary view of the spinal cord circuits that generate gate control","volume":"82","author":"Braz","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.jpain.2023.02.002_bib0007","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fphar.2019.00366","article-title":"Structure-function and therapeutic potential of spider venom-derived cysteine knot peptides targeting sodium channels","volume":"10","author":"Cardoso","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0008","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nn.4571","article-title":"PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1","volume":"20","author":"Chen","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpain.2023.02.002_bib0009","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1167\/iovs.09-3602","article-title":"Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jpain.2023.02.002_bib0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1023\/A:1018969222130","article-title":"Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides","volume":"11","author":"Chikhale","year":"1994","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpain.2023.02.002_bib0011","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","article-title":"PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer atients","volume":"6","author":"Concha-Benavente","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 1","key":"10.1016\/j.jpain.2023.02.002_bib0012","first-page":"153","article-title":"75 years of opioid research: the exciting but vain quest for the Holy Grail","volume":"147","author":"Corbett","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0013","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1016\/j.cub.2019.01.003","article-title":"Protein glycosylation","volume":"29","author":"Eichler","year":"2019","journal-title":"Curr Biol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0014","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1039\/B603083C","article-title":"Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs","volume":"24","author":"Estrada","year":"2007","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.jpain.2023.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jpain.2017.08.007","article-title":"Novel endomorphin analogs are more potent and longer-lasting analgesics in neuropathic, inflammatory, postoperative, and visceral pain relative to morphine","volume":"18","author":"Feehan","year":"2017","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2023.02.002_bib0016","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrn2372","article-title":"General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal","volume":"9","author":"Franks","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jpain.2023.02.002_bib0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1568026043451663","article-title":"New trends in the development of opioid peptide analogues as advanced remedies for pain relief","volume":"4","author":"Gentilucci","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0196-9781(99)00127-8","article-title":"The effect of halogenation on blood-brain barrier permeability of a novel peptide drug","volume":"20","author":"Gentry","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.jpain.2023.02.002_bib0019","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1021\/acs.jmedchem.5b01170","article-title":"Discovery of novel multifunctional ligands with \u03bc\/\u03b4 opioid agonist\/Neurokinin-1 (NK1) antagonist activities for the treatment of pain","volume":"58","author":"Giri","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0020","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/acs.jmedchem.5b01976","article-title":"Bifunctional peptide-based opioid agonist-nociceptin antagonist ligands for dual treatment of acute and neuropathic pain","volume":"59","author":"Guillemyn","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0021","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/jps.10202","article-title":"Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II","volume":"91","author":"Hau","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpain.2023.02.002_bib0022","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jpain.2023.02.002_bib0023","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1073\/pnas.0809422106","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpain.2023.02.002_bib0024","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.jpain.2023.02.002_bib0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.aaf8924","article-title":"Pain regulation by non-neuronal cells and inflammation","volume":"354","author":"Ji","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jpain.2023.02.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101570","article-title":"PD-1 regulates GABAergic neurotransmission and GABA-mediated analgesia and anesthesia","volume":"23","author":"Jiang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.jpain.2023.02.002_bib0027","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0028","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1744-8069-6-86","article-title":"PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects","volume":"6","author":"Kleczkowska","year":"2010","journal-title":"Mol Pain"},{"key":"10.1016\/j.jpain.2023.02.002_bib0029","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.jpain.2023.02.002_bib0030","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/anie.201710407","article-title":"Immune checkpoint PD-1\/PD-L1: is there life beyond antibodies?","volume":"57","author":"Konstantinidou","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.jpain.2023.02.002_bib0031","article-title":"PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity","volume":"5","author":"Lim","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jpain.2023.02.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137386","article-title":"Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia","volume":"5","author":"Liu","year":"2020","journal-title":"Jci Insight"},{"key":"10.1016\/j.jpain.2023.02.002_bib0033","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/jpet.106.106484","article-title":"Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1","volume":"319","author":"Liu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpain.2023.02.002_bib0034","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/med.20222","article-title":"Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs","volume":"32","author":"Liu","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jpain.2023.02.002_bib0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jpain.2023.02.002_bib0036","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/jm1012374","article-title":"Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery","volume":"54","author":"Marsault","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0037","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0038","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.coph.2008.06.002","article-title":"Discovering and improving novel peptide therapeutics","volume":"8","author":"McGregor","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0039","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fimmu.2019.00630","article-title":"PD-1 primarily targets TCR signal in the inhibition of functional T cell activation","volume":"10","author":"Mizuno","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1021\/ml500241n","article-title":"Novel cyclic biphalin analogue with improved antinociceptive properties","volume":"5","author":"Mollica","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpain.2023.02.002_bib0041","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jpain.2023.02.002_bib0042","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1248\/cpb.51.759","article-title":"Synthesis and antinociceptive activity of orally active opioid peptides: improvement of oral bioavailability by esterification","volume":"51","author":"Ogawa","year":"2003","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.jpain.2023.02.002_bib0043","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jcpt.12244","article-title":"Delta opioid agonists: a concise update on potential therapeutic applications","volume":"40","author":"Peppin","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jpain.2023.02.002_bib0044","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.abb.2018.10.011","article-title":"Recent progress in non-opioid analgesic peptides","volume":"660","author":"Perez de Vega","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jpain.2023.02.002_bib0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2174\/0929867323666160427123005","article-title":"Cyclic opioid peptides","volume":"23","author":"Remesic","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114207","article-title":"Pharmacology and therapeutic potential of venom peptides","volume":"181","author":"Robinson","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0047","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10989-016-9534-8","article-title":"Peptides as 'Drugs': the journey so far","volume":"23","author":"Sachdeva","year":"2017","journal-title":"Int J Pept Res Ther"},{"key":"10.1016\/j.jpain.2023.02.002_bib0048","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jprot.2018.05.009","article-title":"Pain therapeutics from cone snail venoms: from Ziconotide to novel non-opioid pathways","volume":"190","author":"Safavi-Hemami","year":"2019","journal-title":"J Proteomics"},{"key":"10.1016\/j.jpain.2023.02.002_bib0049","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40263-013-0107-5","article-title":"Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS drugs"},{"key":"10.1016\/j.jpain.2023.02.002_bib0050","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1021\/jm00123a035","article-title":"Dermorphin analogues carrying an increased positive net charge in their \"message\" domain display extremely high mu opioid receptor selectivity","volume":"32","author":"Schiller","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0051","first-page":"543","article-title":"From natural peptides to market","volume":"50","author":"Schteingart","year":"2017","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0052","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0053","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/0333102419883374","article-title":"PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model","volume":"40","author":"Shi","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2023.02.002_bib0054","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/geno.1994.1562","article-title":"Structure and chromosomal localization of the human PD-1 gene (PDCD1)","volume":"23","author":"Shinohara","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.jpain.2023.02.002_bib0055","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.0c01915","article-title":"Analgesic opioid ligand discovery based on nonmorphinan Scaffolds derived from natural sources","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0056","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/acsmedchemlett.7b00210","article-title":"Cyclic biphalin analogues incorporating a Xylene bridge: synthesis, characterization, and biological profile","volume":"8","author":"Stefanucci","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpain.2023.02.002_bib0057","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1021\/acs.jmedchem.9b01963","article-title":"Potent, efficacious, and stable cyclic opioid peptides with long lasting antinociceptive effect after peripheral administration","volume":"63","author":"Stefanucci","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0058","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.vh.2014.10.002","article-title":"Bioinformatics and evolution of vertebrate nociceptin and opioid receptors","volume":"97","author":"Stevens","year":"2015","journal-title":"Vitam Horm"},{"key":"10.1016\/j.jpain.2023.02.002_bib0059","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.tips.2016.05.002","article-title":"Voltage-gated Ion channels in the PNS: novel therapies for neuropathic pain?","volume":"37","author":"Tibbs","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jpain.2023.02.002_bib0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fphar.2013.00155","article-title":"Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain","volume":"4","author":"Varamini","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0061","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4(+) and CD8(+) T cells via PD-1\/PD-L1-dependent pathway","volume":"109","author":"Wang","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jpain.2023.02.002_bib0062","doi-asserted-by":"crossref","first-page":"eaaw6471","DOI":"10.1126\/scitranslmed.aaw6471","article-title":"Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates","volume":"12","author":"Wang","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpain.2023.02.002_bib0063","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/acs.jmedchem.6b01181","article-title":"Structure-based optimization of multifunctional agonists for opioid and neuropeptide FF receptors with potent nontolerance forming analgesic activities","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0064","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1016\/j.bmcl.2013.07.036","article-title":"N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile","volume":"23","author":"Weltrowska","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jpain.2023.02.002_bib0065","doi-asserted-by":"crossref","first-page":"13063","DOI":"10.1021\/jacs.7b06506","article-title":"The role of disulfide bond replacements in analogues of the Tarantula toxin ProTx-II and their effects on inhibition of the voltage-gated sodium Ion channel Nav1.7","volume":"139","author":"Wright","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jpain.2023.02.002_bib0066","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41573-019-0013-8","article-title":"Antibodies and venom peptides: new modalities for ion channels","volume":"18","author":"Wulff","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpain.2023.02.002_bib0067","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.j.pain.0000460351.30707.c4","article-title":"Shp-1 dephosphorylates TRPV1 in dorsal root ganglion neurons and alleviates CFA-induced inflammatory pain in rats","volume":"156","author":"Xiao","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2023.02.002_bib0068","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s13311-013-0254-x","article-title":"Programmed death 1 deficiency induces the polarization of macrophages\/microglia to the M1 phenotype after spinal cord injury in mice","volume":"11","author":"Yao","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jpain.2023.02.002_bib0069","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2015.12.024","article-title":"Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine","volume":"105","author":"Zadina","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2023.02.002_bib0070","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.jpain.2023.02.002_bib0071","doi-asserted-by":"crossref","first-page":"15709","DOI":"10.1021\/acs.jmedchem.0c01367","article-title":"Synthesis and biological characterization of cyclic disulfide-containing peptide analogs of the multifunctional opioid\/neuropeptide FF receptor agonists that produce long-lasting and nontolerant antinociception","volume":"63","author":"Zhang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpain.2023.02.002_bib0072","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jpain.2023.02.002_bib0073","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s12264-021-00683-y","article-title":"Emerging role of PD-1 in the central nervous system and brain diseases","volume":"37","author":"Zhao","year":"2021","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.jpain.2023.02.002_bib0074","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204114119","article-title":"An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpain.2023.02.002_bib75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnmol.2019.00216","article-title":"T cells as an emerging target for chronic pain therapy","volume":"12","author":"Laumet","year":"2019","journal-title":"Front Mol Neurosci"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590023000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590023000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:11:16Z","timestamp":1761509476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590023000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1526590023000354"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2023.02.002","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1: A New Candidate Target for Analgesic Peptide Design","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by United States Association for the Study of Pain, Inc.","name":"copyright","label":"Copyright"}]}}